Sign up to access the complete lesson and track your progress!
Unlock This CourseMoney talks and nowhere is this more true than in the world of selective breeding and biotechnology. Every scientific breakthrough, every new crop variety and every medical treatment comes with a price tag. Understanding the economics behind these technologies helps us see why some research gets funded whilst others don't and why certain innovations reach the market whilst others remain in laboratories.
The economic impact of selective breeding and biotechnology stretches far beyond simple profit and loss. These technologies can transform entire industries, create new jobs, reduce costs for consumers and even reshape global trade patterns. However, they also require massive investments and can create economic winners and losers.
Key Definitions:
Selective breeding has been an economic game-changer for agriculture. Farmers can produce more food per acre, animals grow faster and produce more milk or eggs and crops become resistant to diseases that would otherwise destroy entire harvests. This means more profit for farmers and cheaper food for consumers.
Modern agriculture is big business and biotechnology has revolutionised how we produce food. From genetically modified crops that resist pests to livestock that grow faster, these innovations have created billions of pounds in economic value worldwide.
When scientists develop a new crop variety through selective breeding or genetic modification, they're not just thinking about biology – they're thinking about money. A successful crop variety can generate millions in revenue, but developing it can cost years of research and testing.
Creating a new crop variety can cost £10-50 million and take 10-15 years. This includes research, testing, regulatory approval and marketing.
Successful varieties can generate hundreds of millions in sales. High-yielding wheat varieties have added billions to global food production value.
Farmers see increased yields, reduced pesticide costs and more predictable harvests, leading to higher profits and food security.
Golden Rice, genetically modified to contain vitamin A, cost over £20 million to develop. Whilst it could prevent blindness in millions of children, economic and political factors have slowed its adoption. This shows how economic considerations can sometimes conflict with humanitarian goals.
The livestock industry has embraced biotechnology to improve efficiency and profitability. From artificial insemination to genetic testing, these technologies help farmers produce better animals more cost-effectively.
Modern livestock breeding programmes require significant upfront investment but can deliver impressive returns. A prize bull's genetic material can be worth millions and selective breeding programmes can improve entire herds over generations.
Selective breeding has increased average milk production per cow by over 400% since 1950. This means fewer cows needed to produce the same amount of milk, reducing costs for farmers and consumers whilst improving environmental efficiency per litre produced.
The medical side of biotechnology represents some of the highest-value applications of selective breeding and genetic technologies. Developing new medicines and treatments requires enormous investment but can save lives and generate substantial profits.
Creating a new medicine typically costs £1-3 billion and takes 10-15 years. Only about 1 in 10,000 potential drugs make it to market. However, successful drugs can generate tens of billions in revenue, making the investment worthwhile for pharmaceutical companies.
Basic research and early testing can cost £100-500 million. Many potential treatments fail at this stage.
Testing on humans costs £500 million-£2 billion. This is the most expensive part of drug development.
Blockbuster drugs can earn £5-20 billion annually, making the massive investment worthwhile.
Human insulin produced by genetically modified bacteria revolutionised diabetes treatment. The global insulin market is worth over £20 billion annually. Companies like Genentech invested millions in developing this technology in the 1970s and 1980s, creating a new industry that has saved millions of lives whilst generating enormous profits.
One of the biggest economic considerations in biotechnology is who owns the rights to new innovations. Patents protect inventors' rights but can also create controversies, especially when they involve living organisms or essential medicines.
Patents give inventors exclusive rights to their innovations for up to 20 years. This encourages investment in research by guaranteeing that successful inventors can profit from their work. However, it also means that life-saving treatments can be expensive during the patent period.
Patents encourage innovation by protecting investments. Companies are more likely to spend billions on research if they know they can recoup their costs. This has led to rapid advances in medical treatments and agricultural productivity.
Not all economic impacts of selective breeding and biotechnology are positive. These technologies can create challenges for small farmers, raise food prices in some cases and create dependencies on large corporations.
Advanced biotechnology often requires significant capital investment, which can favour large companies and wealthy farmers over smaller operations. This can lead to market concentration and reduced competition.
High-tech seeds and treatments can be expensive, making it difficult for small farmers to compete with large agricultural operations.
Different countries have different regulations on biotechnology, creating trade barriers and market access problems.
New technologies can create price swings as markets adjust to increased productivity or new treatment options.
The global seed industry is dominated by just a few large companies. Bayer (which bought Monsanto) controls about 25% of the global seed market. This concentration gives these companies significant power over food production and pricing, raising concerns about market competition and farmer independence.
The economics of selective breeding and biotechnology continue to evolve rapidly. New technologies like gene editing, artificial intelligence in breeding and personalised medicine promise to create new economic opportunities whilst also presenting fresh challenges.
Technologies like CRISPR gene editing are making biotechnology cheaper and more accessible. This could democratise innovation, allowing smaller companies and research institutions to compete with industry giants. At the same time, artificial intelligence is accelerating the pace of discovery, potentially reducing development costs and timelines.
Cheaper, easier-to-use biotechnology tools could level the playing field, allowing more players to enter the market and potentially reducing costs for consumers whilst increasing innovation.
Understanding the economic dimensions of selective breeding and biotechnology helps us make informed decisions about which technologies to support, how to regulate them fairly and how to ensure that their benefits are shared broadly across society. As these technologies continue to advance, their economic impact will only grow, making this knowledge increasingly important for citizens, policymakers and future scientists alike.